Cargando…

Successful treatment of a locally advanced unresectable pancreatic cancer patient with interstitial pneumonitis by conversion surgery following gemcitabine plus nab-paclitaxel chemotherapy: A case report

Conversion surgery is an attractive strategy to improve the outcomes for locally advanced unresectable (UR-LA) pancreatic ductal adenocarcinoma (PDAC). The present case report, presents a case of successful conversion surgery following the treatment of a patient with UR-LA PDAC, suffering from inter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yokota, Tetsuo, Takano, Shigetsugu, Yoshitomi, Hideyuki, Kagawa, Shingo, Furukawa, Katsunori, Takayashiki, Tsukasa, Kuboki, Satoshi, Suzuki, Daisuke, Sakai, Nozomu, Nojima, Hiroyuki, Mishima, Takashi, Nakadai, Eri, Ohtsuka, Masayuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425509/ https://www.ncbi.nlm.nih.gov/pubmed/30931110 http://dx.doi.org/10.3892/mco.2019.1807

Ejemplares similares

Conversion surgery with gemcitabine plus nab-paclitaxel for locally advanced unresectable pancreatic cancer: A case report
por: Okura, Ryosuke, et al.
Publicado: (2018)

Long-term outcomes and significance of preoperative lymphocyte-to-monocyte ratio as a prognostic indicator in patients with invasive pancreatic neoplasms after repeat pancreatectomy
por: Takano, Shigetsugu, et al.
Publicado: (2020)

Is hepatic artery coil embolization useful in distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer?
por: Ueda, Atsuhiko, et al.
Publicado: (2019)

Successful radical surgical resection of initially unresectable intrahepatic cholangiocarcinoma by downsizing chemotherapy with gemcitabine plus cisplatin: a case report
por: Takayanagi, Ryosuke, et al.
Publicado: (2017)

High expression of Krüppel‐like factor 5 is associated with poor prognosis in patients with colorectal cancer
por: Takagi, Yutaka, et al.
Publicado: (2020)

Needle tract seeding recurrence of pancreatic cancer in the gastric wall with paragastric lymph node metastasis after endoscopic ultrasound-guided fine needle aspiration followed by pancreatectomy: a case report and literature review
por: Sato, Nami, et al.
Publicado: (2020)

Differential effects of KRAS mutational status on long-term survival according to the timing of colorectal liver metastases
por: Sakai, Nozomu, et al.
Publicado: (2021)

OLFM4 Enhances STAT3 Activation and Promotes Tumor Progression by Inhibiting GRIM19 Expression in Human Hepatocellular Carcinoma
por: Ashizawa, Yosuke, et al.
Publicado: (2019)

Ischemic gastropathy after distal pancreatectomy with en bloc celiac axis resection versus distal pancreatectomy for pancreatic body/tail cancer()()
por: Nishino, Hitoe, et al.
Publicado: (2019)

Novel treatment strategy with radiofrequency ablation and surgery for pregnant patients with hepatocellular carcinoma: a case report
por: Matsuo, Megumi, et al.
Publicado: (2018)

Usefulness of the MALDI-TOF MS technology with membrane filter protocol for the rapid identification of microorganisms in perioperative drainage fluids of hepatobiliary pancreatic surgery
por: Sogawa, Kazuyuki, et al.
Publicado: (2021)

The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma
por: Kawahara, Kenji, et al.
Publicado: (2022)

Expression of annexin II and stromal tenascin C promotes epithelial to mesenchymal transition and correlates with distant metastasis in pancreatic cancer
por: Yoneura, Naoko, et al.
Publicado: (2018)

Clinical implication of surgical resection for recurrent biliary tract cancer: Does it work or not?
por: Miyazaki, Masaru, et al.
Publicado: (2017)

Yin Yang 1 regulates ITGAV and ITGB1, contributing to improved prognosis of colorectal cancer
por: Sato, Nami, et al.
Publicado: (2022)

Splenic enlargement induced by preoperative chemotherapy is a useful indicator for predicting liver regeneration after resection for colorectal liver metastases
por: Konishi, Takanori, et al.
Publicado: (2020)

Simultaneous brain and lung metastases of pancreatic ductal adenocarcinoma after curative pancreatectomy: a case report and literature review
por: Oka, Yoshito, et al.
Publicado: (2021)

Tumor-suppressive role of Smad ubiquitination regulatory factor 2 in patients with colorectal cancer
por: Sato, Nami, et al.
Publicado: (2022)

Prosaposin, tumor‐secreted protein, promotes pancreatic cancer progression by decreasing tumor‐infiltrating lymphocytes
por: Miyahara, Yoji, et al.
Publicado: (2022)

A case of successfully resected metachronous gastric and gallbladder metastases from pancreatic body cancer
por: Takahashi, Makoto, et al.
Publicado: (2019)

C4b-binding protein α-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pancreatic cancer
por: Sasaki, Kosuke, et al.
Publicado: (2021)

RYBP contributes to improved prognosis in colorectal cancer via regulation of cell cycle, apoptosis and oxaliplatin sensitivity
por: Morinaka, Takashi, et al.
Publicado: (2023)

Semaphorin 3 C enhances putative cancer stemness and accelerates peritoneal dissemination in pancreatic cancer
por: Tomizawa, Satoshi, et al.
Publicado: (2023)

Complement factor B regulates cellular senescence and is associated with poor prognosis in pancreatic cancer
por: Shimazaki, Reiri, et al.
Publicado: (2021)

Fucosylated C4b-binding protein α-chain, a novel serum biomarker that predicts lymph node metastasis in pancreatic ductal adenocarcinoma
por: Sogawa, Kazuyuki, et al.
Publicado: (2021)

Metadherin promotes metastasis by supporting putative cancer stem cell properties and epithelial plasticity in pancreatic cancer
por: Suzuki, Kensuke, et al.
Publicado: (2017)

Grainyhead‐like 2 (GRHL2) regulates epithelial plasticity in pancreatic cancer progression
por: Nishino, Hitoe, et al.
Publicado: (2017)

Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer
por: Kobayashi, Satoshi, et al.
Publicado: (2022)

Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic Cancer
por: Mie, Takafumi, et al.
Publicado: (2023)

Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
por: Vogl, Ursula M., et al.
Publicado: (2019)

The Survival Benefit of Chemoradiotherapy following Induction Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Unresectable Locally Advanced Pancreatic Cancer
por: Takada, Ryoji, et al.
Publicado: (2021)

Pin1 facilitates NF-κB activation and promotes tumour progression in human hepatocellular carcinoma
por: Shinoda, Kimio, et al.
Publicado: (2015)

Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer
por: Kunzmann, Volker, et al.
Publicado: (2014)

Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure
por: Mita, Naoki, et al.
Publicado: (2019)

Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer
por: Hino, Kaori, et al.
Publicado: (2022)

Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma
por: Reni, Michele, et al.
Publicado: (2016)

Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort
por: Wu, Hongyang, et al.
Publicado: (2022)

C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
por: Shirakawa, Tsuyoshi, et al.
Publicado: (2023)

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
por: Chen, Shuling, et al.
Publicado: (2023)

Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis
por: Chae, Heejung, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lt13ihfd2nlphqld2sgc9te4ck